Mineralys Therapeutics Inc
MLYS37.140USD
-0.290-0.77%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.93BMarket Cap
LossP/E TTM
More Details of Mineralys Therapeutics Inc Company
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and in subjects with hypertension and OSA.
Mineralys Therapeutics Inc Info
Ticker SymbolMLYS
Company nameMineralys Therapeutics Inc
IPO dateFeb 10, 2023
CEOCongleton (Jon)
Number of employees51
Security typeOrdinary Share
Fiscal year-endFeb 10
Address150 N. Radnor Chester Road
CityRADNOR
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19087
Phone18883786240
Websitehttps://mineralystx.com/
Ticker SymbolMLYS
IPO dateFeb 10, 2023
CEOCongleton (Jon)
Company Executives of Mineralys Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
487.60K
-26.51%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
38.08K
-26.70%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
487.60K
-26.51%
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
38.08K
-26.70%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Catalys Pacific, LLC
11.25%
RA Capital Management, LP
9.25%
Samsara BioCapital, LLC
7.91%
BlackRock Institutional Trust Company, N.A.
4.03%
The Vanguard Group, Inc.
3.80%
Other
63.75%
Shareholders
Shareholders
Proportion
Catalys Pacific, LLC
11.25%
RA Capital Management, LP
9.25%
Samsara BioCapital, LLC
7.91%
BlackRock Institutional Trust Company, N.A.
4.03%
The Vanguard Group, Inc.
3.80%
Other
63.75%
Shareholder Types
Shareholders
Proportion
Venture Capital
31.11%
Hedge Fund
26.19%
Investment Advisor
25.59%
Investment Advisor/Hedge Fund
15.81%
Private Equity
6.02%
Research Firm
4.04%
Individual Investor
1.50%
Bank and Trust
0.19%
Pension Fund
0.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
315
76.75M
101.61%
+1.04M
2025Q2
287
68.74M
105.48%
+8.03M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Catalys Pacific, LLC
8.90M
11.79%
--
--
Jun 30, 2025
RA Capital Management, LP
7.32M
9.7%
+1.18M
+19.14%
Sep 04, 2025
Samsara BioCapital, LLC
5.67M
7.51%
--
--
Sep 04, 2025
BlackRock Institutional Trust Company, N.A.
2.74M
3.62%
+532.75K
+24.18%
Jun 30, 2025
The Vanguard Group, Inc.
2.32M
3.07%
+283.58K
+13.93%
Jun 30, 2025
Caligan Partners, LP
2.02M
2.67%
-132.31K
-6.16%
Jun 30, 2025
Andera Partners S.A.S.
2.77M
3.66%
-100.00K
-3.49%
Jun 30, 2025
Capital International Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
HBM Partners AG
2.25M
2.97%
--
--
Sep 30, 2024
Suvretta Capital Management, LLC
1.74M
2.31%
+76.73K
+4.60%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Simplify Health Care ETF
7.48%
Invesco Dorsey Wright Healthcare Momentum ETF
2.35%
Virtus LifeSci Biotech Clinical Trials ETF
1.85%
Invesco Dorsey Wright SmallCap Momentum ETF
0.58%
Tema Heart & Health ETF
0.53%
State Street SPDR S&P Biotech ETF
0.32%
iShares Micro-Cap ETF
0.31%
ProShares Ultra Nasdaq Biotechnology
0.27%
Invesco Nasdaq Biotechnology ETF
0.27%
Optimize Strategy Index ETF
0.26%
View more
Simplify Health Care ETF
Proportion7.48%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.35%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.85%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.58%
Tema Heart & Health ETF
Proportion0.53%
State Street SPDR S&P Biotech ETF
Proportion0.32%
iShares Micro-Cap ETF
Proportion0.31%
ProShares Ultra Nasdaq Biotechnology
Proportion0.27%
Invesco Nasdaq Biotechnology ETF
Proportion0.27%
Optimize Strategy Index ETF
Proportion0.26%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Mineralys Therapeutics Inc?
The top five shareholders of Mineralys Therapeutics Inc are:
Catalys Pacific, LLC holds 8.90M shares, accounting for 11.79% of the total shares.
RA Capital Management, LP holds 7.32M shares, accounting for 9.70% of the total shares.
Samsara BioCapital, LLC holds 5.67M shares, accounting for 7.51% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.74M shares, accounting for 3.62% of the total shares.
The Vanguard Group, Inc. holds 2.32M shares, accounting for 3.07% of the total shares.
Catalys Pacific, LLC holds 8.90M shares, accounting for 11.79% of the total shares.
RA Capital Management, LP holds 7.32M shares, accounting for 9.70% of the total shares.
Samsara BioCapital, LLC holds 5.67M shares, accounting for 7.51% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.74M shares, accounting for 3.62% of the total shares.
The Vanguard Group, Inc. holds 2.32M shares, accounting for 3.07% of the total shares.
What are the top three shareholder types of Mineralys Therapeutics Inc?
The top three shareholder types of Mineralys Therapeutics Inc are:
Catalys Pacific, LLC
RA Capital Management, LP
Samsara BioCapital, LLC
Catalys Pacific, LLC
RA Capital Management, LP
Samsara BioCapital, LLC
How many institutions hold shares of Mineralys Therapeutics Inc (MLYS)?
As of 2025Q3, 315 institutions hold shares of Mineralys Therapeutics Inc, with a combined market value of approximately 76.75M, accounting for 101.61% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.87%.
What is the biggest source of revenue for Mineralys Therapeutics Inc?
In --, the -- business generated the highest revenue for Mineralys Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
